We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.00 | 9.41% | 23.25 | 23.00 | 23.50 | 23.50 | 20.50 | 20.75 | 2,429,394 | 16:27:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.79 | 60.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/5/2024 09:12 | Time to rise again | spa362 | |
01/5/2024 09:05 | Unfortunately I don’t think there is any parsortix analysis going on Mr K. 300k participants would goose the share price a little mind you… The ctDNA companies have really cornered the market in screening studies… By virtue of investing millions in studies to be fair. | gspanner | |
01/5/2024 08:34 | Fhmktg, a number of the Professor's running the Transform trial have links to Parsortix.Full article in the Guardian for those with no Telegraph access.https://www.t | mrkeysersoze | |
01/5/2024 07:30 | Certain amount of truth in that...it's now 2 years since FDA...it's been jam tomorrow for a long time but good or bad...I'm still in for the long haul..."One day Thomas"..... | sawney | |
01/5/2024 07:09 | Prostate emerging again as a major interest area for oncology Liquid biopsy will hopefully feature alongside MRI and patient profiling for genetic trends. | fhmktg | |
30/4/2024 20:29 | So many threads full of uninvested pontificaters. Just repeating the same thing over and over. I don't understand the social phenomenon that leads people to do this. This is a different crew to "new profile" derampers. These are some sort of person that derives pleasure from spending their time talking about shares rather than investing in them | bagpuss67 | |
30/4/2024 20:18 | Krypton And anyone also knows there is a mechanism to reduce the nominal value if they can’t get backers at 10p. The good news is the company value is not crazy. The bad is the likely cash level needed v the share price. If you have 260m shares in issue (MC £36m) at 14p and need £20m at 10p, that would mean 460m shares, say 11p open making the MC £50m, yet the burn is over 1m per month. So the claims of below 10p are not fantasy, countless AIM companies have seen share prices destroyed and diluted to oblivion in this market. Angle fortunately have something of apparent value, but years of lack of uptake will be used as leverage against them to push them lower. It’s a bad bargaining position start point. To be concluded in the coming weeks no doubt. Until it’s done everyday (without major deal news) is a gloomy day. Let’s hope results don’t have any, lower than expected, pushed into 2025 etc as the vultures will have even more discount ammo. | ohwhatfun | |
30/4/2024 17:49 | NEW RESEARCH in Sheffield to investigate protein that fuels BREAST cancer. Breast Cancer Now has awarded £250k to Dr Elena Rainero at the UNIVERSITY of SHEFFIELD, to study how BREAST cancer cells use alternative food sources to grow and spread, and the role a protein called a2b1 integrin plays in this process. This research COULD uncover a cancer-specific process which may lead to the development of treatments that come with fewer side effects for patients, as healthy cells won't be affected.Https://onc | 5oletrader | |
30/4/2024 16:48 | Anyone heard of Robert Zeillinger before or any Angle involvement? He appears to have a medical diagnostics company and been involved in funding the above research… | gspanner | |
30/4/2024 16:35 | So worth looking at Mr K’s link… ‘Early access’ via the internet to an EJC article where 473 samples were analysed with parsortix to analyse whether an assay of ESR1 and ERCC1 is predictive Of response in platinum resistant ovarian cancer. It was! It’s a helpful example of how parsotix can become mainstream potentially over a number of tumour sites potentially tailoring therapy for millions of patients… And I would presume the analysis of the 473 patients will hit the bottom line these results… £473k ? (At least) | gspanner | |
30/4/2024 13:24 | Many thanks for the link Mr. K, 'hope all's going well with your treatment. | danwaits | |
30/4/2024 12:15 | You may as well ask your cat. In fact you'd get a more intelligent reply from it. Don't engage. Better to discuss more relevant subjects. | boris cobaka | |
30/4/2024 11:08 | If this is such a certainty with regards to a placing, ie, first 14p, then 10p and now 7p.....Why were there no shorts opened against this company?....explain? | htrocka2 | |
30/4/2024 10:08 | Credit to KOR on Telegram group.https://online | mrkeysersoze | |
30/4/2024 09:48 | Why do you keep posting negative comments....are you trying to make money shorting or hope to buy lower. Yes you are. Foolish.No one cares of your opinion. Worthless. | muffster | |
30/4/2024 08:33 | Clearly cr@p financial results expected and more 'jam' tommorrow from Newland with a subtle hint that 'strategic' options include a cash raise but at what price to 'mug' sorry entice investors I'm going 8p! | bones699 | |
30/4/2024 01:12 | Chunky delayed buy from Friday put thru first thing. Almost 40k. Results coming up. | boris cobaka | |
29/4/2024 21:51 | Angle is getting noticed. This is their LinkedIn page. 12,685 Followers. | outsizeclothes.com | |
29/4/2024 21:20 | Timmmmmberrrrrr Placing anyone ? 7p? | havinthelasttoast | |
29/4/2024 13:57 | Remember the Spanish Inquisition according to Monty Python.......... | liberatingsteptoe | |
29/4/2024 12:52 | Yep I sold half at 16p and the rest this morning for circa 10% less. Definitely still interested as I like the company and expect to buy back much lower after what I expect to be underwhelming results and a raise. | adw198 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions